Clinical Trial Update: Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating VL-PX10 plus VL-P22 for Pulmonary Fibrosis related to COVID-19 has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis

Drugs mentioned

• VL-P22
• VL-PX10

Snippet

Sponsor: Vitti Labs, LLC | Conditions: Pulmonary Fibrosis, COVID-19 Respiratory Infection | Phase 2 | Status: SUSPENDED